- Home
- TLRY vs ACRS Comparison
TLRY vs ACRS Comparison
Compare TLRY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | ACRS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.9M | 608.9M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TLRY | ACRS |
|---|---|---|
| Price | $4.64 | $5.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $72.33 | $10.20 |
| AVG Volume (30 Days) | ★ 3.4M | 1.4M |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $8.79 | N/A |
| Revenue Next Year | $19.98 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $1.38 |
| 52 Week High | $15.70 | $5.15 |
Technical Indicators
Market Signals| Indicator | TLRY | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 58.64 |
| Support Level | $1.14 | $4.13 |
| Resistance Level | $5.71 | $5.15 |
| Average True Range (ATR) | 0.25 | 0.27 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 15.71 | 71.85 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.